Lundbeck backs Trintellix with new data

New clinical data from a trial involving Lundbeck's Trintellix in patients with depression and anxiety will put wind in the drug's sails.
Photo: Jens Dresling
Photo: Jens Dresling
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

A particular group of patients have proven to benefit from being treated with Lundbeck's Trintellix/Brintellix – a group which has otherwise had difficulty finding treatment, according to a Lundbeck press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading